StockData

Crescent Biopharma vs Pyxis Oncology

CBIO and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

cbioCrescent Biopharma$14.15+8.4% in 1 yearpyxsPyxis Oncology$1.58−63.8% in 1 year

How CBIO and PYXS compare

Crescent Biopharma is the larger company, worth 4.0 times as much as Pyxis Oncology ($526M against $132M).

Crescent Biopharma scores higher on the StockData Score (10 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCBIOPYXS
Size and price
Market cap$526M$132M
Share price$14.15$1.58
Change, 1 year8.4%−63.8%
Change, 5 years−92.5%−87.8%
Beta (5Y)1.631.61
Employees4456
StockData Score
Total score10 (better)5
Valuation score1 (better)0
Growth score1 (better)0
Performance score2 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S35.0×–
P/B1.9× (better)3.2×
FCF yield−15.7%–
Growth
Revenue growth, 5Y average1.3%–
Profitability
Operating margin−1217%–
Net margin−728%–
FCF margin−550%–
Return on equity−55.8% (better)−158%
Financial health
Debt / equity0.000.00
Current ratio12.57 (better)2.96
Altman Z-score10.43 (better)−10.32
Piotroski F-score–1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions79.7%40.9%
Held by insiders38.6%20.4%
Insider net buying, 12 months$29.1M (better)−$107K
Short interest, % of float18.3%6.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.